^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TMB-L

    i
    Other names: TMB | Tumor Mutational Burden
    Related biomarkers:
    Expression
    Others
    Apply
    Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study (NCT04392505)
    Phase 2
    Oslo University Hospital
    Active, not recruiting
    Last update posted :
    02/29/2024
    Initiation :
    05/11/2020
    Primary completion :
    05/01/2025
    Completion :
    05/01/2033
    PD-L1 • TMB
    |
    TMB-H • TMB-L
    |
    Imfinzi (durvalumab)
    Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (CheckMate 568) (NCT02659059)
    Phase 2
    Bristol-Myers Squibb
    Completed
    Last update posted :
    04/05/2023
    Initiation :
    02/15/2016
    Primary completion :
    06/22/2018
    Completion :
    03/07/2022
    PD-L1 • TMB
    |
    PD-L1 expression • TMB-H • PD-L1 negative • TMB-L
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed
    A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC (NCT03546452)
    Phase N/A
    Shanghai Chest Hospital
    Unknown status
    Last update posted :
    06/07/2018
    Initiation :
    05/18/2018
    Primary completion :
    09/30/2018
    Completion :
    05/01/2019
    TMB
    |
    TMB-H • TMB-L